{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:04:46Z","timestamp":1792073086520,"version":"4.4.0"},"reference-count":61,"publisher":"American Diabetes Association","issue":"7","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2001,7,1]]},"abstract":"<jats:p>Effects of aminoguanidine and aspirin on the development of retinopathy have been examined in 5-year studies of diabetic dogs. Either agent was administered daily in doses of 20\u201325 mg\u2009\u00b7\u2009kg\u22121\u2009\u00b7\u2009day\u22121. Because severity of hyperglycemia greatly influences development of the retinopathy, special effort was devoted to maintaining comparable glycemia in experimental and control groups. The retinal vasculature was isolated by the trypsin digest method, and retinopathy was assessed by light microscopy. Diabetes for 5 years resulted, as expected, in saccular capillary aneurysms, pericyte ghosts, acellular capillaries, retinal hemorrhages, and other lesions. Administration of aminoguanidine essentially prevented the retinopathy, significantly inhibiting the development of retinal microaneurysms, acellular capillaries, and pericyte ghosts compared with diabetic controls. Aspirin significantly inhibited the development of retinal hemorrhages and acellular capillaries over the 5 years of study, but had less effect on other lesions. Although diabetes resulted in significantly increased levels of advanced glycation end products (AGEs) (namely, pentosidine in tail collagen and aorta, and Hb-AGE), aminoguanidine had no significant influence on these parameters of glycation. Nitration of a retinal protein was significantly increased in diabetes and inhibited by aminoguanidine. The biochemical mechanism by which aminoguanidine has inhibited retinopathy thus is not clear. Aminoguanidine (but not aspirin) inhibited a diabetes-induced defect in ulnar nerve conduction velocity, but neither agent was found to influence kidney structure or albumen excretion.<\/jats:p>","DOI":"10.2337\/diabetes.50.7.1636","type":"journal-article","created":{"date-parts":[[2007,3,6]],"date-time":"2007-03-06T14:04:22Z","timestamp":1173189862000},"page":"1636-1642","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":196,"title":["Pharmacological Inhibition of Diabetic Retinopathy"],"prefix":"10.2337","volume":"50","author":[{"given":"Timothy S.","family":"Kern","sequence":"first","affiliation":[{"name":"Departments of Medicine and Ophthalmology, and Center for Diabetes Research, Case Western Reserve University, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald L.","family":"Engerman","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Research, University of Wisconsin, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031206393338500_R1","doi-asserted-by":"crossref","unstructured":"Engerman RL, Bloodworth JMB Jr, Nelson S: Relationship of microvascular disease in diabetes to metabolic control. Diabetes\u200826:760\u2013769, 1977","DOI":"10.2337\/diabetes.26.8.760"},{"key":"2022031206393338500_R2","doi-asserted-by":"crossref","unstructured":"Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med\u2008329:977\u2013986, 1993","DOI":"10.1056\/NEJM199309303291401"},{"key":"2022031206393338500_R3","doi-asserted-by":"crossref","unstructured":"Engerman RL, Kern TS: Experimental galactosemia produces diabetic-like retinopathy. Diabetes\u200833:97\u2013100, 1984","DOI":"10.2337\/diabetes.33.1.97"},{"key":"2022031206393338500_R4","unstructured":"Robison WG Jr, Nagata M, Laver N, Hohman TC, Kinoshita JH: Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. Invest Ophthalmol Vis Sci\u200830:2285\u20132292, 1989"},{"key":"2022031206393338500_R5","doi-asserted-by":"crossref","unstructured":"Takahashi Y, Augustin W, Wyman M, Kador PF: Quantitative analysis of retinal vessel changes in galactose-fed dogs. J Ocular Pharmacol\u20089:257\u2013269, 1993","DOI":"10.1089\/jop.1993.9.257"},{"key":"2022031206393338500_R6","doi-asserted-by":"crossref","unstructured":"Engerman RL, Kern TS: Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs. Diabetes\u200842:820\u2013825, 1993","DOI":"10.2337\/diabetes.42.6.820"},{"key":"2022031206393338500_R7","doi-asserted-by":"crossref","unstructured":"Kern TS, Engerman RL: Comparison of retinal lesions in alloxan-diabetic rats and galactose-fed rats. Curr Eye Res\u200813:863\u2013867, 1994","DOI":"10.3109\/02713689409015087"},{"key":"2022031206393338500_R8","doi-asserted-by":"crossref","unstructured":"Kern TS, Engerman RL: A mouse model of diabetic retinopathy. Arch Ophthalmol\u2008114:986\u2013990, 1996","DOI":"10.1001\/archopht.1996.01100140194013"},{"key":"2022031206393338500_R9","doi-asserted-by":"crossref","unstructured":"DAMAD Study Group: Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy: a multicenter randomized controlled clinical trial. Diabetes\u200838:491\u2013498, 1989","DOI":"10.2337\/diabetes.38.4.491"},{"key":"2022031206393338500_R10","doi-asserted-by":"crossref","unstructured":"Early Treatment of Diabetic Retinopathy Research Group: Effects of aspirin treatment on diabetic retinopathy. Ophthalmol\u200898:757\u2013765, 1991","DOI":"10.1016\/S0161-6420(13)38010-5"},{"key":"2022031206393338500_R11","doi-asserted-by":"crossref","unstructured":"Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science\u2008232:1629\u20131632, 1986","DOI":"10.1126\/science.3487117"},{"key":"2022031206393338500_R12","doi-asserted-by":"crossref","unstructured":"Kochakian M, Manjula BN, Egan JJ: Chronic dosing with aminoguanidine and novel advanced glycosylation end product\u2013formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats. Diabetes\u200845:1694\u20131700, 1996","DOI":"10.2337\/diab.45.12.1694"},{"key":"2022031206393338500_R13","doi-asserted-by":"crossref","unstructured":"Odetti PR, Borgoglio A, DePascale A, Rolandi R, Adezati L: Prevention of diabetes-increased aging effect on rat collagen\u2013linked fluorescence by aminoguanidine and rutin. Diabetes\u200839:796\u2013801, 1990","DOI":"10.2337\/diabetes.39.7.796"},{"key":"2022031206393338500_R14","doi-asserted-by":"crossref","unstructured":"Cameron NE, Cotter MA, Dines K, Love A: Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia\u200835:946\u2013950, 1992","DOI":"10.1007\/BF00401423"},{"key":"2022031206393338500_R15","doi-asserted-by":"crossref","unstructured":"Corbett JA, Tilton RG, Chang K, Hasan KS, Ido Y, Wang JL, Sweetland MA, Lancaster JR Jr, Williamson JR, McDaniel ML: Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes\u200841:552\u2013556, 1992","DOI":"10.2337\/diab.41.4.552"},{"key":"2022031206393338500_R16","doi-asserted-by":"crossref","unstructured":"Ellis EN, Good BH: Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism\u200840:1016\u20131019, 1991","DOI":"10.1016\/0026-0495(91)90122-D"},{"key":"2022031206393338500_R17","doi-asserted-by":"crossref","unstructured":"Kihara M, Schmelzer JD, Poduslo JF, Curran GL, Nickander KK, Low PA: Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci U S A\u200888:6107\u20136111, 1991","DOI":"10.1073\/pnas.88.14.6107"},{"key":"2022031206393338500_R18","doi-asserted-by":"crossref","unstructured":"Li YM, Steffes M, Donnelly T, Liu C, Fuh H, Basgen J, Bucala R, Vlassara H: Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. Proc Natl Acad Sci U S A\u200893:3902\u20133907, 1996","DOI":"10.1073\/pnas.93.9.3902"},{"key":"2022031206393338500_R19","doi-asserted-by":"crossref","unstructured":"Soulis T, Sastra S, Thallas V, Mortensen SB, Wilkin M, Clausen JT, Bjerrum OJ, Petersen H, Lau J, Jerums G, Boel E, Cooper ME: A novel inhibitor of advanced glycation end-product formation inhibits mesenteric vascular hypertrophy in experimental diabetes. Diabetologia\u200842:472\u2013479, 1999","DOI":"10.1007\/s001250051181"},{"key":"2022031206393338500_R20","doi-asserted-by":"crossref","unstructured":"Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G: Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int\u200850:627\u2013634, 1996","DOI":"10.1038\/ki.1996.358"},{"key":"2022031206393338500_R21","doi-asserted-by":"crossref","unstructured":"Hammes H-P, Martin S, Federlin K, Geisen K, Brownlee M: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A\u200888:11555\u201311558, 1991","DOI":"10.1073\/pnas.88.24.11555"},{"key":"2022031206393338500_R22","doi-asserted-by":"crossref","unstructured":"Hammes H-P, Syed S, Uhlmann M, Weiss A, Federlin K, Geisub K, Brownlee M: Aminoguanidine does not inhibit the initial phase of experimental diabetic retinopathy in rats. Diabetologia\u200838:269\u2013273, 1995","DOI":"10.1007\/BF00400629"},{"key":"2022031206393338500_R23","unstructured":"Kern TS, Tang J, Mizutani M, Kowluru RA, Nagaraj RH, Romeo G, Podesta F, Lorenzi M: Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci\u200841:3972\u20133978., 2000"},{"key":"2022031206393338500_R24","doi-asserted-by":"crossref","unstructured":"Engerman RL, Finkelstein D, Aguirre G, Diddie K, Fox R, Frank R, Varma S: Appropriate animal models for research on human diabetes mellitus and its complications: ocular complications. Diabetes\u200831 (Suppl. 1):82\u201388, 1982","DOI":"10.2337\/diab.31.1.S82"},{"key":"2022031206393338500_R25","doi-asserted-by":"crossref","unstructured":"Engerman RL, Kern TS: Retinopathy in animal models of diabetes. Diabetes Metab Rev\u200811:109\u2013120, 1995","DOI":"10.1002\/dmr.5610110203"},{"key":"2022031206393338500_R26","doi-asserted-by":"crossref","unstructured":"Trinder P: Rapid determination of salicylate in biological fluids. Biochem J\u200857:301\u2013305, 1954","DOI":"10.1042\/bj0570301"},{"key":"2022031206393338500_R27","doi-asserted-by":"crossref","unstructured":"Engerman RL, Kern TS: Progression of incipient diabetic retinopathy during good glycemic control. Diabetes\u200836:808\u2013812, 1987","DOI":"10.2337\/diabetes.36.7.808"},{"key":"2022031206393338500_R28","doi-asserted-by":"crossref","unstructured":"Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R: Hemoglogin-AGE: a circulating marker of advanced glycosylation. Science\u2008258:651\u2013653, 1992","DOI":"10.1126\/science.1411574"},{"key":"2022031206393338500_R29","doi-asserted-by":"crossref","unstructured":"Monnier VM, Sell DR, Abdul-Karim FW, Emancipator SN: Collagen browning and cross-linking are increased in chronic experimental hyperglycemia: relevance to diabetes and aging. Diabetes\u200837:867\u2013872, 1988","DOI":"10.2337\/diabetes.37.7.867"},{"key":"2022031206393338500_R30","doi-asserted-by":"crossref","unstructured":"Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, Tatemichi N, Takei Y: Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest\u200899:1272\u20131280, 1997","DOI":"10.1172\/JCI119285"},{"key":"2022031206393338500_R31","doi-asserted-by":"crossref","unstructured":"Kern TS, Engerman RL: Platelet aggregation in experimental diabetes and experimental galactosemia. Diabetes\u200833:846\u2013850, 1984","DOI":"10.2337\/diabetes.33.9.846"},{"key":"2022031206393338500_R32","doi-asserted-by":"crossref","unstructured":"Naveh-Floman N, Weissman C, Belkin M: Arachidonic acid metabolism by retinas of rats with streptozotocin-induced diabetes. Curr Eye Res\u20083:1135\u20131139, 1984","DOI":"10.3109\/02713688409000813"},{"key":"2022031206393338500_R33","doi-asserted-by":"crossref","unstructured":"Engerman RL, Kern TS, Larson ME: Nerve conduction velocity in dogs is reduced by diabetes and not by galactosemia. Metabolism\u200839:638\u2013640, 1990","DOI":"10.1016\/0026-0495(90)90032-8"},{"key":"2022031206393338500_R34","doi-asserted-by":"crossref","unstructured":"Engerman RL, Kern TS, Larson ME: Nerve conduction and aldose reductase inhibition during 5 years of diabetes or galactosemia in dogs. Diabetologia\u200837:141\u2013144, 1994","DOI":"10.1007\/s001250050084"},{"key":"2022031206393338500_R35","doi-asserted-by":"crossref","unstructured":"Bilous RW, Mauer SM, Sutherland DER, Steffes MW: Mean glomerular volume and rate of development of diabetic nephropathy. Diabetes\u200838:1142\u20131147, 1989","DOI":"10.2337\/diabetes.38.9.1142"},{"key":"2022031206393338500_R36","doi-asserted-by":"crossref","unstructured":"Kern TS, Engerman RL: Urinary protein excretion rates in experimentally diabetic dogs and experimentally galactosaemic dogs. Diabetologia\u200831:928\u2013932, 1988","DOI":"10.1007\/BF00265379"},{"key":"2022031206393338500_R37","doi-asserted-by":"crossref","unstructured":"Arauz-Pacheco C, Ramirez LC, Pruneda L, Sanborn GE, Rosenstock J, Raskin P: The effect of the aldose reductase inhibitor, ponalrestat, on the progression of diabetic retinopathy. J Diabetes Complications\u20086:131\u2013137, 1992","DOI":"10.1016\/1056-8727(92)90024-F"},{"key":"2022031206393338500_R38","doi-asserted-by":"crossref","unstructured":"Sorbinil Retinopathy Trial Research Group: A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol\u2008108:1234\u20131244, 1990","DOI":"10.1001\/archopht.1990.01070110050024"},{"key":"2022031206393338500_R39","unstructured":"Bresnick G, Engerman R, Davis MD, de Venecia G, Myers FL: Patterns of ischemia in diabetic retinopathy. Trans Am Acad Ophthalmol Otolaryngol\u200881:694\u2013709, 1976"},{"key":"2022031206393338500_R40","doi-asserted-by":"crossref","unstructured":"Tilton RG, Chang K, Hasan KS, Smith SR, Petrash JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML, Williamson JR: Prevention of diabetic vascular dysfunction by guanidines: inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes\u200842:221\u2013232, 1993","DOI":"10.2337\/diab.42.2.221"},{"key":"2022031206393338500_R41","doi-asserted-by":"crossref","unstructured":"Soulis-Liparota T, Cooper M, Dunlop M, Jerums G: The relative roles of advanced glycation, oxidation and aldose reductase inhibition in the development of experimental diabetic nephropathy in the Sprague-Dawley rat. Diabetologia\u200838:387\u2013394, 1995","DOI":"10.1007\/BF00410275"},{"key":"2022031206393338500_R42","doi-asserted-by":"crossref","unstructured":"Yu PH, Zuo DM: Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications. Diabetologia\u200840:1243\u20131250, 1997","DOI":"10.1007\/s001250050816"},{"key":"2022031206393338500_R43","doi-asserted-by":"crossref","unstructured":"do Carmo A, Lopes C, Santos M, Proenca R, Cunha-Vaz J, Carvalho AP: Nitric oxide synthase activity and l-arginine metabolism in the retinas from streptozotocin-induced diabetic rats. Gen Pharmacol\u200830:319\u2013324, 1998","DOI":"10.1016\/S0306-3623(97)00363-7"},{"key":"2022031206393338500_R44","doi-asserted-by":"crossref","unstructured":"Giardino I, Fard AK, Hatchell DL, Brownlee M: Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes\u200847:1114\u20131120, 1998","DOI":"10.2337\/diabetes.47.7.1114"},{"key":"2022031206393338500_R45","unstructured":"Kowluru RA, Engerman RL, Kern TS: Effects of aminoguanidine on hyperglycemia-induced retinal metabolic abnormalities (Abstract). Diabetes\u200848 (Suppl. 1):A19, 1999"},{"key":"2022031206393338500_R46","unstructured":"Kern TS, Tang J, Mizutani M, Kowluru RA, Nagaraj RH, Romeo G, Podesta F, Lorenzi M: Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia. Invest Ophthalmol Vis Sci\u200841:3972\u20133978, 2000"},{"key":"2022031206393338500_R47","doi-asserted-by":"crossref","unstructured":"Kern TS, Engerman RL: Arrest of glomerulopathy in diabetic dogs by improved glycemic control. Diabetologia\u200833:522\u2013525, 1990","DOI":"10.1007\/BF00404138"},{"key":"2022031206393338500_R48","doi-asserted-by":"crossref","unstructured":"Engerman RL, Kern TS: Hyperglycemia and development of glomerular pathology: diabetes compared with galactosemia. Kidney Int\u200836:41\u201345, 1989","DOI":"10.1038\/ki.1989.158"},{"key":"2022031206393338500_R49","doi-asserted-by":"crossref","unstructured":"Engerman RL, Kern TS: Dissociation of retinopathy and nephropathy in animal models of diabetes: diabetes vs. galactosemia. In Hyperglycemia, Diabetes and Vascular Disease . Ruderman N, Williamson J, Brownlee M, Eds. New York, Oxford University Press, 1992, p. 151\u2013161","DOI":"10.1007\/978-1-4614-7524-8_8"},{"key":"2022031206393338500_R50","doi-asserted-by":"crossref","unstructured":"Powell ED, Field RA: Diabetic retinopathy and rheumatoid arthritis. Lancet\u20082:17\u201318, 1964","DOI":"10.1016\/S0140-6736(64)90008-X"},{"key":"2022031206393338500_R51","unstructured":"Carroll WW, Geeraets WJ: Diabetic retinopathy and salicylates. Ann Ophthalmol\u20084:1019\u20131046, 1972"},{"key":"2022031206393338500_R52","doi-asserted-by":"crossref","unstructured":"Engerman RL, Kern TS: Retinopathy in galactosemic dogs continues to progress after cessation of galactosemia. Arch Ophthalmol\u2008113:355\u2013358, 1995","DOI":"10.1001\/archopht.1995.01100030111032"},{"key":"2022031206393338500_R53","doi-asserted-by":"crossref","unstructured":"Feke GT, Yoshida A, Ogasawara H, Konno S, Goger DG, Buzney SM, McMeel JW: Retinal blood flow increases following short-term aspirin usage in type I diabetics with no or minimal retinopathy. Ophthalmic Res\u200828:108\u2013116, 1996","DOI":"10.1159\/000267882"},{"key":"2022031206393338500_R54","unstructured":"Pournaras C, Tsacopoulos M: [The metabolic regulation of the retinal blood flow and the role of prostaglandins (author\u2019s transl)]. Klin Monatsbl Augenheilkd\u2008172:445\u2013448, 1978"},{"key":"2022031206393338500_R55","doi-asserted-by":"crossref","unstructured":"Yue DK, McLennan S, Handelsman DJ, Delbridge L, Reeve T, Turtle JR: The effect of salicylates on nonenzymatic glycosylation and thermal stability of collagen in diabetic rats. Diabetes\u200833:745\u2013751, 1984","DOI":"10.2337\/diab.33.8.745"},{"key":"2022031206393338500_R56","doi-asserted-by":"crossref","unstructured":"Brownlee M: Nonenzymatic glycosylation of macromolecules: prospects of pharmacologic modulation. Diabetes\u200841 (Suppl. 2):57\u201360, 1992","DOI":"10.2337\/diab.41.2.S57"},{"key":"2022031206393338500_R57","doi-asserted-by":"crossref","unstructured":"Edelstein D, Brownlee M: Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes\u200841:26\u201329, 1992","DOI":"10.2337\/diabetes.41.1.26"},{"key":"2022031206393338500_R58","doi-asserted-by":"crossref","unstructured":"Sajithlal GB, Chithra P, Chandrakasan G: Advanced glycation end products induce crosslinking of collagen in vitro. Biochim Biophys Acta\u20081407:215\u2013224, 1998","DOI":"10.1016\/S0925-4439(98)00043-X"},{"key":"2022031206393338500_R59","doi-asserted-by":"crossref","unstructured":"Althaus JS, Andrus PK, Williams CM, VonVoigtlander PF, Cazers AR, Hall ED: The use of salicylate hydroxylation to detect hydroxyl radical generation in ischemic and traumatic brain injury: reversal by tirilazad mesylate (U-74006F). Mol Chem Neuropathol\u200820:147\u2013162, 1993","DOI":"10.1007\/BF02815368"},{"key":"2022031206393338500_R60","doi-asserted-by":"crossref","unstructured":"Dinis TC, Maderia VM, Almeida LM: Action of phenolic derivatives (acetaminophen, salicylate, and 5-aminosalicylate) as inhibitors of membrane lipid peroxidation and as peroxyl radical scavengers. Arch Biochem Biophys\u2008315:161\u2013169, 1994","DOI":"10.1006\/abbi.1994.1485"},{"key":"2022031206393338500_R61","doi-asserted-by":"crossref","unstructured":"Boeri D, Maiello M, Lorenzi M: Increased prevalence of microthrombosis in retinal capillaries of diabetic individuals. Diabetes\u200850:1432\u20131439, 2001","DOI":"10.2337\/diabetes.50.6.1432"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/50\/7\/1636\/367563\/1636.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/50\/7\/1636\/367563\/1636.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T12:10:52Z","timestamp":1667391052000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/50\/7\/1636\/11784\/Pharmacological-Inhibition-of-Diabetic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7,1]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,7,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diabetes.50.7.1636","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,7,1]]}}}